Table 3 The treatment between the progressive and stable patients
From: The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, China
Total (N = 333) | Mild-moderate (N = 254) | Severe-critical (N = 79) | P value | |
|---|---|---|---|---|
Treatment | ||||
Antiviral therapy | 333 | 254 | 79 | |
Antibiotic therapy | 99 (29.7%) | 51 (20.1%) | 48 (60.8%) | < 0.001 |
Use of corticosteroid | 90 (27.0%) | 22 (8.67%) | 68 (86.1%) | < 0.001 |
Use of gamma globulin | 81 (24.3%) | 18 (7.1%) | 63 (79.7%) | < 0.001 |
Regulate intestinal flora | 179 (53.8%) | 123 (48.4%) | 56 (70.1%) | < 0.001 |
Oxygen support | 238 (71.5%) | 160 (63.0%) | 79 (100.0%) | |
Nasal cannula | 181 (54.4%) | 157 (61.8%) | 23 (29.1%) | < 0.001 |
Mask oxygen inhalation | 7 (2.1%) | 3 (1.2%) | 4 (5.1%) | 0.036 |
High-flow nasal cannula | 10 (3.0%) | 0 | 10 (12.7%) | |
Non-invasive ventilation | 24 (7.2%) | 0 | 24 (30.4%) | |
Invasive mechanical ventilation | 13 (3.9%) | 0 | 13 (16.5%) | |
Invasive mechanical ventilation + ECOM | 5 (1.5%) | 0 | 5 (6.3%) | |
Acute respiratory distress syndrome | 13 (3.9%) | 0 | 13 (16.5%) | |